ArticleScientific reports2026
A splicing-derived microRNA from amelogenin exon4 regulates enamel formation via control of exon4 splicing and amelogenin expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Amelogenin, essential for enamel formation, is encoded by the alternatively spliced gene Amelx/AMELX, with exon4 splicing producing major protein isoforms and a microRNA (miR-exon4). We previously reported that miR-exon4 regulates osteoblast and ameloblast function via the Nfia- and Prkch-Runx2 axis and may be involved in X-linked Amelogenesis Imperfecta associated with exon4 splicing defects. This study investigates miR-exon4’s role in enamel defect development and exon4 splicing. A miR-exon4 mimic or inhibitor was applied to mouse pups during enamel development. One-week inhibition of miR-exon4 reduced enamel mineralization, shortened the early mineralization phase, and lowered RUNX2 expression, leading to increased Amelx mRNA and amelogenin protein levels. A 24-hour inhibition enhanced exon4 splicing without affecting overall Amelx expression, suggesting a direct role in splicing regulation. MiR-exon4 inhibition also altered the expression of Serine/Arginine-rich splicing factors (SRSFs), indicating indirect modulation of exon4 splicing. Nuclear localization of miR-exon4 was confirmed using an Amelx minigene, and a mutant form that reduced nuclear miR-exon4 levels impaired its binding to Amelx pre-mRNA. A binding site of miR-exon4 at the intron4 branch point further supports its direct involvement in exon4 splicing. These findings suggest a role for miR-exon4 in regulating both amelogenin expression and exon4 splicing, leading to enamel defects when absent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.